MIT engineers create nanoparticles for delivering personalized cancer vaccines
The particles carry a customized dose of cancer antigens that can provoke a strong immune response against tumors.
Search Stories
Reprogrammed NK immune cells target cancer and autoimmune disorders
A new approach can program these cells inside the body and shows promise against diseases caused by dysfunctional T cells, including lymphoma and autoimmune hepatitis.
A new approach to cancer vaccination yields more powerful T cells
Using immune-remodeling mRNA molecules, researchers generated T cells that can slow tumor growth and, in some cases, eradicate tumors.
Study reveals why some cancer therapies don’t work for all patients
A backup survival pathway can help tumor cells resist certain lung cancer and other drugs. Combining therapies may offer a solution.
Improving AI models’ ability to explain their predictions
A new approach could help users know whether to trust a model’s predictions in safety-critical applications like health care and autonomous driving.
Turning on an immune pathway in tumors could lead to their destruction
MIT researchers show they can use messenger RNA to activate the pathway and trigger the immune system to attack tumors.
New nanoparticles stimulate the immune system to attack ovarian tumors
Targeted particles carrying the cytokine IL-12 can jump-start T cells, allowing them to clear tumors while avoiding side effects.
Helping the immune system attack tumors
Stefani Spranger is working to discover why some cancers don’t respond to immunotherapy, in hopes of making them more vulnerable to it.
Unlocking mRNA’s cancer-fighting potential
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
Hitchhiking cancer vaccine makes progress in the clinic
MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
Immune action at a distance
MIT and MGH researchers design a local, gel-based drug-delivery platform that may provoke a system-wide immune response to metastatic tumors.
A snapshot of cancer vaccine development
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
Vaccine delivers a boost to T cell therapy
The new strategy may enable engineered T cells to eradicate solid tumors such as glioblastoma.
Gamifying medical data labeling to advance AI
MIT alumnus’ platform taps the wisdom of crowds to label medical data for AI companies.
Putting the STING into cancer immunotherapy
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.